Sign inJoin waitlistJoin the waitlist

Suresh Ramalingam

Executive Director · Winship Cancer Institute at Emory Midtown

Credentials: · · · · ·

History

Winship Cancer Institute at Emory Midtown
Present
Winship Cancer Institute at Emory Midtown
Present
Emory University School of Medicine
Present

Hematology and Medical Oncology
UPMC
2000–2003
Internal Medicine
Wayne State University School of Medicine
1992–1994
Kilpauk Medical College
1988–1992
University

Research

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 4,542 citations
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
New England Journal of Medicine · 2017 · 2,877 citations
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
New England Journal of Medicine · 2018 · 2,498 citations

Taofeek Owonikoko
124 papers · 6 as a fellow
FK
Fadlo Khuri
85 papers
CB
Chandra Belani
68 papers
RP
Rathi Pillai
44 papers · 8 as a fellow
Conor Steuer
42 papers · 10 as a fellow
Gabriel Sica
34 papers
Walter Curran
33 papers
Kristin Higgins
31 papers
David Gandara
30 papers · 10 as a fellow
Nabil Saba
26 papers
Dong Shin
25 papers
Hossein Borghaei
24 papers

Grants

Emory University Lung Cancer SPORE
National Cancer Institute · P50
Contact PI · $2.2M · Emory University
2026–2031
Deciphering LKB1-Associated Immunotherapy Resistance in Lung Adenocarcinoma (LUAD)
National Cancer Institute · P01
PI · $8.6M · Emory University
2022–2028
Winship Cancer Institute Cancer Center Support Grant
National Cancer Institute · P30
Contact PI · $19.1M · Emory University
2009–2028
Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE
National Cancer Institute · P50
Contact PI · $10.1M · Emory University
2019–2025

Clinical trials

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Principal investigator · Recruiting · Phase 3
AstraZeneca
2024–2029
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Principal investigator · Recruiting · Early phase 1
Emory University
2022–2028
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2018–2027
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
Principal investigator · Terminated · Phase 1
ACEA Therapeutics, Inc.
2015–2019